| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
61,820,000 |
| Market
Cap: |
127.97(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1.62 - $4.13 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Poseida Therapeutics is a clinical-stage biopharmaceutical company. Co.'s chimeric antigen receptor T cell (CAR-T) product candidate includes P-BCMA-101, which is an autologous CAR-T being developed for the treatment of patients with metastatic castrate resistant prostate cancer. Co.'s dual CAR-T allogeneic program candidates include P-CD19CD20-ALLO1, which is an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for B cell leukemia and lymphoma indications and some autoimmune disease. Co.'s gene therapy programs include P-OTC-101, which is an in vivo liver-directed gene therapy candidate for the treatment of ornithine transcarbamylase deficiency.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
2,292,857 |
| Total Buy Value |
$0 |
$0 |
$0 |
$8,025,000 |
| Total People Bought |
0 |
0 |
0 |
2 |
| Total Buy Transactions |
0 |
0 |
0 |
2 |
| Total Shares Sold |
0 |
0 |
0 |
160,696 |
| Total Sell Value |
$0 |
$0 |
$0 |
$592,808 |
| Total People Sold |
0 |
0 |
0 |
1 |
| Total Sell Transactions |
0 |
0 |
0 |
1 |
| End Date |
2024-01-25 |
2023-10-24 |
2023-04-25 |
2022-04-25 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Malin Life Sciences Holdings Ltd |
10% Owner |
– – • |
2022-08-08 |
4 |
B |
$3.50 |
$7,525,000 |
D/D |
2,150,000 |
11,835,673 |
2.45 |
43% |
|
| Ostertag Eric |
Executive Chairman |
• • • |
2022-08-08 |
4 |
AB |
$3.50 |
$500,000 |
D/D |
142,857 |
838,824 |
|
43% |
|
| Ostertag Eric |
Executive Chairman |
• • • |
2022-08-03 |
4 |
AS |
$3.69 |
$592,808 |
I/I |
(160,696) |
0 |
|
41% |
|
| Lloyd Marcea Bland |
Director |
– • – |
2022-06-16 |
4 |
A |
$0.00 |
$0 |
D/D |
19,650 |
29,650 |
|
- |
|
| Baum Charles M |
Director |
– • – |
2022-06-16 |
4 |
A |
$0.00 |
$0 |
D/D |
39,300 |
39,300 |
|
- |
|
| Schmid John P. |
Director |
– • – |
2022-06-16 |
4 |
A |
$0.00 |
$0 |
D/D |
19,650 |
19,650 |
|
- |
|
| Corning Luke |
Director |
– • – |
2022-06-16 |
4 |
A |
$0.00 |
$0 |
D/D |
19,650 |
19,650 |
|
- |
|
| Collins Cynthia |
Director |
– • – |
2022-06-16 |
4 |
A |
$0.00 |
$0 |
D/D |
19,650 |
19,650 |
|
- |
|
| Ingalls Kerry D. |
Chief Operating Officer |
• – – |
2022-03-16 |
4 |
B |
$3.98 |
$11,940 |
D/D |
3,000 |
55,000 |
2.74 |
-33% |
|
| Mylet Johanna |
Chief Financial Officer |
• – – |
2022-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
50,000 |
84,231 |
|
- |
|
| Leonhardt Harry J |
GC & Chief Compliance Officer |
• – – |
2022-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
50,000 |
50,000 |
|
- |
|
| Warner Brent |
President, Gene Therapy |
• – – |
2022-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
307,881 |
307,881 |
|
- |
|
| Spear Matthew A. |
Chief Medical Officer |
• – – |
2022-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
50,000 |
111,485 |
|
- |
|
| Ingalls Kerry D. |
Chief Operating Officer |
• – – |
2022-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
50,000 |
52,000 |
|
- |
|
| Ostertag Eric |
Executive Chairman |
• • • |
2022-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
89,500 |
692,967 |
|
- |
|
| Gergen Mark J |
President and CEO |
• • – |
2022-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
357,200 |
357,200 |
|
- |
|
| Ostertag Eric |
Executive Chairman |
• • • |
2021-12-30 |
4 |
GD |
$0.00 |
$0 |
I/I |
48,902 |
580,292 |
|
- |
|
| Ostertag Eric |
Executive Chairman |
• • • |
2021-12-30 |
4 |
GD |
$0.00 |
$0 |
D/D |
93,955 |
603,467 |
|
- |
|
| Mylet Johanna |
Chief Financial Officer |
• – – |
2021-12-21 |
4 |
OE |
$1.17 |
$9,061 |
D/D |
5,716 |
34,231 |
|
- |
|
| Spear Matthew A. |
Chief Medical Officer |
• – – |
2021-12-06 |
4 |
OE |
$1.32 |
$13,220 |
D/D |
10,000 |
61,485 |
|
- |
|
| Malin Life Sciences Holdings Ltd |
Common director with Issuer |
– – • |
2021-12-06 |
4 |
B |
$6.90 |
$12,613 |
D/D |
1,828 |
9,685,673 |
2.37 |
-46% |
|
| Malin Life Sciences Holdings Ltd |
Common director with Issuer |
– – • |
2021-12-02 |
4 |
B |
$6.88 |
$29,550 |
D/D |
4,296 |
9,683,845 |
2.37 |
-42% |
|
| Malin Life Sciences Holdings Ltd |
Common director with Issuer |
– – • |
2021-12-01 |
4 |
B |
$6.85 |
$125,806 |
D/D |
18,365 |
9,679,549 |
2.45 |
-37% |
|
| Malin Life Sciences Holdings Ltd |
Common director with Issuer |
– – • |
2021-11-30 |
4 |
B |
$6.85 |
$195,838 |
D/D |
28,592 |
9,661,184 |
2.45 |
-39% |
|
| Malin Life Sciences Holdings Ltd |
Common director with Issuer |
– – • |
2021-11-18 |
4 |
B |
$7.18 |
$511,685 |
D/D |
71,312 |
9,567,501 |
2.45 |
-35% |
|
65 Records found
|
|
Page 1 of 3 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.09 (4.17%) 
